The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls

European Journal of Haematology

Volumn 58, Issue 4, 1997, Pages 279-285

  Burgess, J K ^b   Chong, B H ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b NONE

Author keywords

heparin; heparinoid; ICU patients; platelet aggregation

Indexed keywords

DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

EID: 0031007008     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01667.x     Document Type: Article

References (17)

1. HORNE III MK. Heparin binding to normal and abnormal platelets. Thromb Res 1988: 51: 135-144.
2. HORNE III MK, CHAO ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990: 74: 306-312.
3. SOBEL M, ADELMAN B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 1988: 50: 815-826.
4. CHONG BH, BERNDT MC. Heparin-induced thrombocytopenia. Blut 1989: 58: 53-57.
5. SALZMAN EW, ROSENBERG RD, SMITH MH, LINDON JN. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980: 65: 64-73.
6. CHONG BH, ISMAIL F. The mechanism of heparin-induced platelet aggregation. Eur J Haematol 1989: 43: 245-251.
7. CHONG BH, CASTALDI PA. Brief Communications: platelet proaggregating effect of heparin: possible mechanism for non-immune heparin-associated thrombocytopenia. Aust NZ J Med 1986: 16: 715-716.
8. NELSON JC, LERNER RG, GOLDSTEIN R. Heparin-induced thrombocytopenia. Arch Intern Med 1978: 138: 548.
9. BRACE LD, FAREED J. Heparin-induced platelet aggregation. II. Dose/response relationships for two low molecular weight heparin fractions (CY 216 and CY 222). Thromb Res 1990: 59: 1-14.
10. MIKHAILIDIS DP, BARRADAS MA, MIKHAILIDIS AM, MAGNANI H, DANDONA P. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol 1984: 17: 43-48.
11. THOMSON C, FORBES CD, PRENTICE CRM. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med 1973: 45: 485-494.
12. MACINTYRE DE, HANDIN RI, ROSENBERG R, SALZMAN EW. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation. Thromb Res 1981: 22: 167-175.
13. MIKHAILIDIS DP, BARRADAS MA, JEREMY JY, GRACEY L, WAKELING A, DANDONA P. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest 1985: 15: 313-319.
14. GREINACHER A, DROST W, MICHELS I, et al. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. Ann Hematol 1992: 64: 40-42.
15. SHERIDAN D, CARTER C, KELTON JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986: 67: 27-30.
16. WESTWICK J, SCULLY MF, POLL C, KAKKAR VV. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 1986: 42: 435-447.
17. CASU B, JOHNSON EA, MANTOVANI M, et al. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates. Arzneimittelforschung 1983: 33: 135-142.